OA12.04 Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.

Treatment options are limited in patients with extensive stage small cell lung cancer (ES-SCLC) after progression on first line chemo-immunotherapy (CIT). Temozolomide (TEM) is active in ES-SCLC and has been shown to have immunomodulatory impact in patients with advanced cancers, however data are unavailable in patients after CIT. We present the final analysis of a phase 2 trial of combination nivolumab and TEM in patients with ES-SCLC as 2nd or 3rd line after progression on CIT.